MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.anai.2024.09.015

Медицинская библиотека · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024

Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.

Bachert Claus, Khan Asif H, Hopkins Claire, Han Joseph K, Fokkens Wytske J, Mannent Leda P, Msihid Jérôme, Borsos Kinga, Kamat Siddhesh, Nash Scott, Sacks Harry, Rowe Paul J, Deniz Yamo, Jacob-Nara Juby A

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Frequently reported outcomes of clinical trials in chronic rhinosinusitis with nasal polyps (CRSwNP) may have limited relatability for patients.

OBJECTIVE

To enhance the patient relatability of outcomes in dupilumab clinical trials for CRSwNP, daily symptom scores were used to determine new patient‑centered end points: mild-to-no-symptom months (MSM) and symptom-free months (SFM).

METHODS

This work is a post hoc analysis of patients receiving dupilumab 300 mg or placebo every 2 weeks for 24 weeks (SINUS-24 study; NCT02912468) or 52 weeks (SINUS‑52; NCT02898454). Patients recorded symptom severity scores daily for each of nasal congestion, loss of smell, and anterior and posterior rhinorrhea on a scale of 0 to 3 (0 = no symptoms; 1 = mild; 2 = moderate; 3 = severe). We assessed the proportions of patients reporting only MSM or SFM throughout the 28‑day period before randomization, week 24 (pooled studies), and week 52 (SINUS‑52).

RESULTS

Significantly more dupilumab‑treated than placebo-treated patients achieved MSM for all 4 symptoms (week 24: 31.0% vs 4.4%; odds ratio [OR] 12.9 [95% CI 6.4-25.8]; week 52: 38.3% vs 2.6%; OR 15.6 [5.9-41.0]; both P < .0001). In addition, significantly more dupilumab-treated than placebo‑treated patients achieved SFM for at least 1 of the 4 symptoms (week 24: 35.4% vs 10.8%; OR 4.9 [95% CI 3.1-7.8]; week 52: 50.0% vs 9.2%; OR 9.1 [95% CI 4.6-17.9]; both P < .0001).

CONCLUSION

One-third of patients with severe CRSwNP treated with dupilumab achieved MSM for all 4 cardinal symptoms (nasal congestion, loss of smell, and anterior and posterior rhinorrhea). Moreover, half of the patients achieved SFM for at least 1 of the 4 symptoms. These results support the benefit of dupilumab in improving patient‑centered outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52).

Для цитирования: Bachert Claus, Khan Asif H, Hopkins Claire, Han Joseph K, Fokkens Wytske J, Mannent Leda P, Msihid Jérôme, Borsos Kinga, Kamat Siddhesh, Nash Scott, Sacks Harry, Rowe Paul J, Deniz Yamo, Jacob-Nara Juby A. Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024. DOI: 10.1016/j.anai.2024.09.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.